Maria Fredin Grupper: Privilege to Represent WSO at the Coalition for Access to NCD Medicines and Products
Maria Fredin Grupper, Executive Director at World Stroke Organization, shared on LinkedIn:
”From Commitment to impact: Scaling Access to NCD Medicines and Products
It was a privilege to represent the World Stroke Organization at the 2026 Annual Meeting of the Coalition for Access to NCD Medicines and Products in Nairobi last week.
Bringing together ministerial representatives from seven African countries, people with lived experience, civil society, regional organizations, academia, and the private sector, the meeting was a powerful reminder of what is possible when diverse partners unite around a common goal.
The discussions focused on progress since the Fourth UN High-Level Meeting on NCDs HLM4 and, more importantly, on what it will take to accelerate action.
The message was unequivocal: achieving SDG 3.4 and UHC will require sustained investment, stronger health systems, resilient supply chains, and equitable access to essential NCD medicines, products, and services through primary health care.
Countries shared tangible examples of how political commitment is being translated into action.
These experiences demonstrate that solutions exist—and that meaningful change is achievable.
The greatest lesson from the meeting was simple: no country can do this alone.
By sharing experiences, learning from one another, and working across sectors and borders, we can move beyond commitments and deliver real impact for the millions of people living with NCDs.
I was especially encouraged to see stroke receiving greater recognition within national NCD strategies.
Stroke remains one of the leading causes of death and disability worldwide, and ensuring equitable access to prevention, acute care, rehabilitation, and long-term support must remain a global priority.
The challenge ahead is not whether we know what works—it is whether we have the collective determination to scale it!”

Stay updated with Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian